Skip to content

Switch to atazanavir associated with cholesterol and triglyceride reductions

How much can we trust statistical models of the HIV epidemic?

Caribbean states announce first regional deal for cheaper ARVs

Scaling up MTCT programmes: learning from Zambia

Protease inhibitors may disappear within three years, predicts Robert Gallo

Superinfection despite strong immune response to existing virus

Impact of immigration and international travel on UK HIV and STI epidemics

Protease inhibitors and heart disease - more evidence of risk

The positives and negatives of involving people with HIV in NGOs